182 related articles for article (PubMed ID: 26002042)
1. Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Imrichova D; Messingerova L; Seres M; Kavcova H; Pavlikova L; Coculova M; Breier A; Sulova Z
Eur J Pharm Sci; 2015 Sep; 77():29-39. PubMed ID: 26002042
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates.
Messingerova L; Imrichova D; Kavcova H; Turakova K; Breier A; Sulova Z
Toxicol In Vitro; 2015 Oct; 29(7):1405-15. PubMed ID: 26009263
[TBL] [Abstract][Full Text] [Related]
3. The expression of P-glycoprotein in leukemia cells is associated with the upregulated expression of nestin, a class 6 filament protein.
Coculova M; Imrichova D; Seres M; Messingerova L; Bohacova V; Sulova Z; Breier A
Leuk Res; 2016 Sep; 48():32-9. PubMed ID: 27479651
[TBL] [Abstract][Full Text] [Related]
4. Vincristine-induced expression of P-glycoprotein in MOLM-13 and SKM-1 acute myeloid leukemia cell lines is associated with coexpression of nestin transcript.
Imrichova D; Coculova M; Messingerova L; Sulova Z; Breier A
Gen Physiol Biophys; 2014; 33(4):425-31. PubMed ID: 24968412
[TBL] [Abstract][Full Text] [Related]
5. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines.
Bailly JD; Muller C; Jaffrézou JP; Demur C; Gassar G; Bordier C; Laurent G
Leukemia; 1995 May; 9(5):799-807. PubMed ID: 7769842
[TBL] [Abstract][Full Text] [Related]
6. The expression of P-gp in leukemia cells is associated with cross-resistance to protein N-glycosylation inhibitor tunicamycin.
Pavlikova L; Seres M; Imrichova D; Hano M; Rusnak A; Zamorova M; Katrlik J; Breier A; Sulova Z
Gen Physiol Biophys; 2016 Oct; 35(4):497-510. PubMed ID: 27763330
[TBL] [Abstract][Full Text] [Related]
7. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R
Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the ABCB1 drug transporter in acute myeloid leukemia cells is associated with downregulation of latrophilin-1.
Kocibalova Z; Guzyova M; Imrichova D; Sulova Z; Breier A
Gen Physiol Biophys; 2018 May; 37(3):353-357. PubMed ID: 29938681
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large.
Friesen C; Roscher M; Hormann I; Leib O; Marx S; Moreno J; Miltner E
Eur J Cancer; 2013 Jul; 49(11):2542-54. PubMed ID: 23684782
[TBL] [Abstract][Full Text] [Related]
11. A decrease in cellular microRNA-27a content is involved in azacytidine-induced P-glycoprotein expression in SKM-1 cells.
Messingerova L; Imrichova D; Kavcova H; Seres M; Sulova Z; Breier A
Toxicol In Vitro; 2016 Oct; 36():81-88. PubMed ID: 27396688
[TBL] [Abstract][Full Text] [Related]
12. P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients.
Tang R; Cohen S; Perrot JY; Faussat AM; Zuany-Amorim C; Marjanovic Z; Morjani H; Fava F; Corre E; Legrand O; Marie JP
BMC Cancer; 2009 Jun; 9():199. PubMed ID: 19549303
[TBL] [Abstract][Full Text] [Related]
13. Targeting acute myeloid leukemia cells by CD33 receptor-specific MoS
Štefík P; Annušová A; Lakatoš B; Elefantová K; Čepcová L; Hofbauerová M; Kálosi A; Jergel M; Majková E; Šiffalovič P
Biomed Mater; 2021 Aug; 16(5):. PubMed ID: 34280914
[TBL] [Abstract][Full Text] [Related]
14. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB
Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327
[TBL] [Abstract][Full Text] [Related]
15. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
Naito K; Takeshita A; Shigeno K; Nakamura S; Fujisawa S; Shinjo K; Yoshida H; Ohnishi K; Mori M; Terakawa S; Ohno R
Leukemia; 2000 Aug; 14(8):1436-43. PubMed ID: 10942240
[TBL] [Abstract][Full Text] [Related]
16. [Multidrug resistance in acute leukemia].
Takeshita A; Ohno R
Rinsho Ketsueki; 1996 Aug; 37(8):640-6. PubMed ID: 8827870
[TBL] [Abstract][Full Text] [Related]
17. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein depresses cisplatin sensitivity in L1210 cells by inhibiting cisplatin-induced caspase-3 activation.
Gibalová L; Sereš M; Rusnák A; Ditte P; Labudová M; Uhrík B; Pastorek J; Sedlák J; Breier A; Sulová Z
Toxicol In Vitro; 2012 Apr; 26(3):435-44. PubMed ID: 22269388
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
20. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
